Fintel reports that on November 5, 2024, JP Morgan downgraded their outlook for Neumora Therapeutics (NasdaqGS:NMRA) from Overweight to Neutral. Analyst Price Forecast Suggests 116.52% Upside As of ...
Commissions do not affect our editors' opinions or evaluations. Small-cap stocks are among the most volatile equity investments, although they can reward investors with the potential for higher ...